A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

Trial Details

NCT ID
NCT06990880
Phase
PHASE1 / PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • GSK5458514
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Denver, Colorado, United States|39.73915,-104.9847
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • East Brunswick, New Jersey, United States|40.42788,-74.41598

Key Eligibility Criteria

  • Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and re…
  • Male participants greater than equal to (\>=)18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) a…
  • Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after …
  • Refrain from donating sperm

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →